Zoonotic Infections: Previous page | 1,2,3,4,5,6

References

Zoonotic Infections Overview Anthrax Hepatitis E Plague Rabies References

[1] Gao F, Bailes E, Robertson DL, Chen Y, Rodenburg CM, Michael SF, et al. Origin of HIV-1 in the chimpanzee Pan troglodytes troglodytes. Nature 1999;397:436-41.

[2] Korber B, Muldoon M, Theiler J, Gao F, Gupta R, Lapedes A, et al. Timing the ancestor of the HIV-1 pandemic strains. Science 2000;288:1789-96.

[3] Brachman PS, Friedlander AM, Grabenstein JD. Anthrax vaccines. In: Plotkin SA, Orenstein WA, Offit P, editors. Vaccine 5th ed. Philadelphia: Saunders, Elsevier, 2008: 111-27.

[4] Dixon TC, Meselson M, Guillemin J, Hanna PC. Anthrax. N Engl J Med 1999;341:815-26.

[5] Schwartz RS. Racial profiling in medical research. N Engl J Med 2001;344:1392-3.

[6] Holty JE, Bravata DM, Liu H, Olshen RA, McDonald KM, Owens DK. Systematic review: a century of inhalational anthrax cases from 1900 to 2005. Ann Intern Med 2006;144:270-80.

[7] Update: Investigation of bioterrorism-related anthrax, 2001. MMWR Morb Mortal Wkly Rep 2001;50:1008-10.

[8] Wallin A, Luksiene Z, Zagminas K, Surkiene G. Public health and bioterrorism: renewed threat of anthrax and smallpox. Medicina (Kaunas) 2007;43:278-84.

[9] Fasanella A, Palazzo L, Petrella A, Quaranta V, Romanelli B, Garofolo G. Anthrax in red deer (Cervus elaphus), Italy. Emerg Infect Dis 2007;13:1118-9.

[10] Collier RJ, Young JA. Anthrax toxin. Annu Rev Cell Dev Biol 2003;19:45-70.

[11] Duesbery NS, Webb CP, Leppla SH, Gordon VM, Klimpel KR, Copeland TD, et al. Proteolytic inactivation of MAP-kinase-kinase by anthrax lethal factor. Science 1998;280:734-7.

[12] Leppla SH. Anthrax toxin edema factor: a bacterial adenylate cyclase that increases cyclic AMP concentrations of eukaryotic cells. Proc Natl Acad Sci U S A 1982;79:3162-6.

[13] Gupta M, Alam S, Bhatnagar R. Catalytically inactive anthrax toxin(s) are potential prophylactic agents. Vaccine 2007;25:8410-9.

[14] Sterne M. Distribution and economic importance of anthrax. Fed Proc 1967;26:1493-5.

[15] Green BD, Battisti L, Koehler TM, Thorne CB, Ivins BE. Demonstration of a capsule plasmid in Bacillus anthracis. Infect Immun 1985;49:291-7.

[16] Ivins BE, Ezzell JW, Jr., Jemski J, Hedlund KW, Ristroph JD, Leppla SH. Immunization studies with attenuated strains of Bacillus anthracis. Infect Immun 1986;52:454-8.

[17] Passalacqua KD, Bergman NH. Bacillus anthracis: interactions with the host and establishment of inhalational anthrax. Future Microbiol 2006;1:397-415.

[18] World Health Organ ( WHO). WHO guidelines on Anthrax in human and animals. Geneva; 2008.

[19] Turnbull PC. Anthrax vaccines: past, present and future. Vaccine 1991;9:533-9.

[20] Brey RN. Molecular basis for improved anthrax vaccines. Adv Drug Deliv Rev 2005;57:1266-92.

[21] Pittman PR, Hack D, Mangiafico J, Gibbs P, McKee KT, Jr., Friedlander AM, et al. Antibody response to a delayed booster dose of anthrax vaccine and botulinum toxoid. Vaccine 2002;20:2107-15.

[22] Pittman PR, Kim-Ahn G, Pifat DY, Coonan K, Gibbs P, Little S, et al. Anthrax vaccine: immunogenicity and safety of a dose-reduction, route-change comparison study in humans. Vaccine 2002;20:1412-20.

[23] Marano N, Plikaytis BD, Martin SW, Rose C, Semenova VA, Martin SK, et al. Effects of a reduced dose schedule and intramuscular administration of anthrax vaccine adsorbed on immunogenicity and safety at 7 months: a randomized trial. JAMA 2008;300:1532-43.

[24] Fellows PF, Linscott MK, Ivins BE, Pitt ML, Rossi CA, Gibbs PH, et al. Efficacy of a human anthrax vaccine in guinea pigs, rabbits, and rhesus macaques against challenge by Bacillus anthracis isolates of diverse geographical origin. Vaccine 2001;19:3241-7.

[25] Baillie L. The development of new vaccines against Bacillus anthracis. J Appl Microbiol 2001;91:609-13.

[26] Goodman L. Taking the sting out of the anthrax vaccine. J Clin Invest 2004;114:868-9.

[27] Phipps AJ, Premanandan C, Barnewall RE, Lairmore MD. Rabbit and nonhuman primate models of toxin-targeting human anthrax vaccines. Microbiol Mol Biol Rev 2004;68:617-29.

[28] Tournier JN, Ulrich RG, Quesnel-Hellmann A, Mohamadzadeh M, Stiles BG. Anthrax, toxins and vaccines: a 125-year journey targeting Bacillus anthracis. Expert Rev Anti Infect Ther 2009;7:219-36.

[29] Makino S, Uchida I, Terakado N, Sasakawa C, Yoshikawa M. Molecular characterization and protein analysis of the cap region, which is essential for encapsulation in Bacillus anthracis. J Bacteriol 1989;171:722-30.

[30] Little SF, Ivins BE, Fellows PF, Friedlander AM. Passive protection by polyclonal antibodies against Bacillus anthracis infection in guinea pigs. Infect Immun 1997;65:5171-5.

[31] Ivins BE, Pitt ML, Fellows PF, Farchaus JW, Benner GE, Waag DM, et al. Comparative efficacy of experimental anthrax vaccine candidates against inhalation anthrax in rhesus macaques. Vaccine 1998;16:1141-8.

[32] Scorpio A, Blank TE, Day WA, Chabot DJ. Anthrax vaccines: Pasteur to the present. Cell Mol Life Sci 2006;63:2237-48.

[33] Wimer-Mackin S, Hinchcliffe M, Petrie CR, Warwood SJ, Tino WT, Williams MS, et al. An intranasal vaccine targeting both the Bacillus anthracis toxin and bacterium provides protection against aerosol spore challenge in rabbits. Vaccine 2006;24:3953-63.

[34] Campbell JD, Clement KH, Wasserman SS, Donegan S, Chrisley L, Kotloff KL. Safety, reactogenicity and immunogenicity of a recombinant protective antigen anthrax vaccine given to healthy adults. Hum Vaccin 2007;3:205-11.

[35] Boyaka PN, Tafaro A, Fischer R, Leppla SH, Fujihashi K, McGhee JR. Effective mucosal immunity to anthrax: neutralizing antibodies and Th cell responses following nasal immunization with protective antigen. J Immunol 2003;170:5636-43.

[36] Gaur R, Gupta PK, Banerjea AC, Singh Y. Effect of nasal immunization with protective antigen of Bacillus anthracis on protective immune response against anthrax toxin. Vaccine 2002;20:2836-9.

[37] Bielinska AU, Janczak KW, Landers JJ, Makidon P, Sower LE, Peterson JW, et al. Mucosal immunization with a novel nanoemulsion-based recombinant anthrax protective antigen vaccine protects against Bacillus anthracis spore challenge. Infect Immun 2007;75:4020-9.

[38] Yin Y, Zhang J, Dong D, Liu S, Guo Q, Song X, et al. Chimeric hepatitis B virus core particles carrying an epitope of anthrax protective antigen induce protective immunity against Bacillus anthracis. Vaccine 2008;26:5814-21.

[39] Bandurska K, Brodzik R, Spitsin S, Kohl T, Portocarrero C, Smirnov Y, et al. Plant-produced hepatitis B core protein chimera carrying anthrax protective antigen domain-4. Hybridoma (Larchmt) 2008;27:241-7.

[40] Gauthier YP, Tournier JN, Paucod JC, Corre JP, Mock M, Goossens PL, et al. Efficacy of a vaccine based on protective antigen and killed spores against experimental inhalational anthrax. Infect Immun 2009;77:1197-207.

[41] Sloat BR, Shaker DS, Le UM, Cui Z. Nasal immunization with the mixture of PA63, LF, and a PGA conjugate induced strong antibody responses against all three antigens. FEMS Immunol Med Microbiol 2008;52:169-79.

[42] Fasanella A, Tonello F, Garofolo G, Muraro L, Carattoli A, Adone R, et al. Protective activity and immunogenicity of two recombinant anthrax vaccines for veterinary use. Vaccine 2008;26:5684-8.

[43] Jameel S. Molecular biology and pathogenesis of hepatitis E virus. Expert Rev Mol Med 1999;1999:1-16.

[44] Labrique AB, Thomas DL, Stoszek SK, Nelson KE. Hepatitis E: an emerging infectious disease. Epidemiol Rev 1999;21:162-79.

[45] Acharya SK, Panda SK. Hepatitis E virus: epidemiology, diagnosis, pathology and prevention. Trop Gastroenterol 2006;27:63-8.

[46] Panda SK, Thakral D, Rehman S. Hepatitis E virus. Rev Med Virol 2007;17:151-80.

[47] Chandra V, Taneja S, Kalia M, Jameel S. Molecular biology and pathogenesis of hepatitis E virus. J Biosci 2008;33:451-64.

[48] Worm HC, Wirnsberger G. Hepatitis E vaccines: progress and prospects. Drugs 2004;64:1517-31.

[49] Khuroo MS, Kamili S, Yattoo GN. Hepatitis E virus infection may be transmitted through blood transfusions in an endemic area. J Gastroenterol Hepatol 2004;19:778-84.

[50] Mast EE, Kuramoto IK, Favorov MO, Schoening VR, Burkholder BT, Shapiro CN, et al. Prevalence of and risk factors for antibody to hepatitis E virus seroreactivity among blood donors in Northern California. J Infect Dis 1997;176:34-40.

[51] Thomas DL, Yarbough PO, Vlahov D, Tsarev SA, Nelson KE, Saah AJ, et al. Seroreactivity to hepatitis E virus in areas where the disease is not endemic. J Clin Microbiol 1997;35:1244-7.

[52] Mansuy JM, Legrand-Abravanel F, Calot JP, Peron JM, Alric L, Agudo S, et al. High prevalence of anti-hepatitis E virus antibodies in blood donors from South West France. J Med Virol 2008;80:289-93.

[53] van der Poel WH, Verschoor F, van der Heide R, Herrera MI, Vivo A, Kooreman M, et al. Hepatitis E virus sequences in swine related to sequences in humans, The Netherlands. Emerg Infect Dis 2001;7:970-6.

[54] Huang FF, Haqshenas G, Guenette DK, Halbur PG, Schommer SK, Pierson FW, et al. Detection by reverse transcription-PCR and genetic characterization of field isolates of swine hepatitis E virus from pigs in different geographic regions of the United States. J Clin Microbiol 2002;40:1326-32.

[55] Pei Y, Yoo D. Genetic characterization and sequence heterogeneity of a canadian isolate of Swine hepatitis E virus. J Clin Microbiol 2002;40:4021-9.

[56] Tei S, Kitajima N, Takahashi K, Mishiro S. Zoonotic transmission of hepatitis E virus from deer to human beings. Lancet 2003;362:371-3.

[57] Takahashi K, Kitajima N, Abe N, Mishiro S. Complete or near-complete nucleotide sequences of hepatitis E virus genome recovered from a wild boar, a deer, and four patients who ate the deer. Virology 2004;330:501-5.

[58] Huang FF, Sun ZF, Emerson SU, Purcell RH, Shivaprasad HL, Pierson FW, et al. Determination and analysis of the complete genomic sequence of avian hepatitis E virus (avian HEV) and attempts to infect rhesus monkeys with avian HEV. J Gen Virol 2004;85:1609-18.

[59] Tei S, Kitajima N, Ohara S, Inoue Y, Miki M, Yamatani T, et al. Consumption of uncooked deer meat as a risk factor for hepatitis E virus infection: an age- and sex-matched case-control study. J Med Virol 2004;74:67-70.

[60] Matsuda H, Okada K, Takahashi K, Mishiro S. Severe hepatitis E virus infection after ingestion of uncooked liver from a wild boar. J Infect Dis 2003;188:944.

[61] Zheng Y, Ge S, Zhang J, Guo Q, Ng MH, Wang F, et al. Swine as a principal reservoir of hepatitis E virus that infects humans in eastern China. J Infect Dis 2006;193:1643-9.

[62] Feagins AR, Opriessnig T, Guenette DK, Halbur PG, Meng XJ. Detection and characterization of infectious Hepatitis E virus from commercial pig livers sold in local grocery stores in the USA. J Gen Virol 2007;88:912-7.

[63] Kamar N, Selves J, Mansuy JM, Ouezzani L, Peron JM, Guitard J, et al. Hepatitis E virus and chronic hepatitis in organ-transplant recipients. N Engl J Med 2008;358:811-7.

[64] Hamid SS, Atiq M, Shehzad F, Yasmeen A, Nissa T, Salam A, et al. Hepatitis E virus superinfection in patients with chronic liver disease. Hepatology 2002;36:474-8.

[65] Emerson SU, Purcell RH. Hepatitis E virus. Rev Med Virol 2003;13:145-54.

[66] Patra S, Kumar A, Trivedi SS, Puri M, Sarin SK. Maternal and fetal outcomes in pregnant women with acute hepatitis E virus infection. Ann Intern Med 2007;147:28-33.

[67] Khuroo MS, Teli MR, Skidmore S, Sofi MA, Khuroo MI. Incidence and severity of viral hepatitis in pregnancy. Am J Med 1981;70:252-5.

[68] Balayan MS. Epidemiology of hepatitis E virus infection. J Viral Hepat 1997;4:155-65.

[69] Prusty BK, Hedau S, Singh A, Kar P, Das BC. Selective suppression of NF-kBp65 in hepatitis virus-infected pregnant women manifesting severe liver damage and high mortality. Mol Med 2007;13:518-26.

[70] Reyes GR, Purdy MA, Kim JP, Luk KC, Young LM, Fry KE, et al. Isolation of a cDNA from the virus responsible for enterically transmitted non-A, non-B hepatitis. Science 1990;247:1335-9.

[71] Reyes GR, Huang CC, Tam AW, Purdy MA. Molecular organization and replication of hepatitis E virus (HEV). Arch Virol Suppl 1993;7:15-25.

[72] Arankalle VA, Paranjape S, Emerson SU, Purcell RH, Walimbe AM. Phylogenetic analysis of hepatitis E virus isolates from India (1976-1993). J Gen Virol 1999;80 ( Pt 7):1691-700.

[73] Graff J, Zhou YH, Torian U, Nguyen H, St Claire M, Yu C, et al. Mutations within potential glycosylation sites in the capsid protein of hepatitis E virus prevent the formation of infectious virus particles. J Virol 2008;82:1185-94.

[74] Emerson SU, Zhang M, Meng XJ, Nguyen H, St Claire M, Govindarajan S, et al. Recombinant hepatitis E virus genomes infectious for primates: importance of capping and discovery of a cis-reactive element. Proc Natl Acad Sci U S A 2001;98:15270-5.

[75] Emerson SU, Nguyen H, Graff J, Stephany DA, Brockington A, Purcell RH. In vitro replication of hepatitis E virus (HEV) genomes and of an HEV replicon expressing green fluorescent protein. J Virol 2004;78:4838-46.

[76] Tanaka T, Takahashi M, Kusano E, Okamoto H. Development and evaluation of an efficient cell-culture system for Hepatitis E virus. J Gen Virol 2007;88:903-11.

[77] Takahashi M, Tanaka T, Azuma M, Kusano E, Aikawa T, Shibayama T, et al. Prolonged fecal shedding of hepatitis E virus (HEV) during sporadic acute hepatitis E: evaluation of infectivity of HEV in fecal specimens in a cell culture system. J Clin Microbiol 2007;45:3671-9.

[78] Robinson RA, Burgess WH, Emerson SU, Leibowitz RS, Sosnovtseva SA, Tsarev S, et al. Structural characterization of recombinant hepatitis E virus ORF2 proteins in baculovirus-infected insect cells. Protein Expr Purif 1998;12:75-84.

[79] Tsarev SA, Tsareva TS, Emerson SU, Govindarajan S, Shapiro M, Gerin JL, et al. Successful passive and active immunization of cynomolgus monkeys against hepatitis E. Proc Natl Acad Sci U S A 1994;91:10198-202.

[80] Tsarev SA, Tsareva TS, Emerson SU, Govindarajan S, Shapiro M, Gerin JL, et al. Recombinant vaccine against hepatitis E: dose response and protection against heterologous challenge. Vaccine 1997;15:1834-8.

[81] Clayson ET, Shrestha MP, Vaughn DW, Snitbhan R, Shrestha KB, Longer CF, et al. Rates of hepatitis E virus infection and disease among adolescents and adults in Kathmandu, Nepal. J Infect Dis 1997;176:763-6.

[82] Shrestha MP, Scott RM, Joshi DM, Mammen MP, Jr., Thapa GB, Thapa N, et al. Safety and efficacy of a recombinant hepatitis E vaccine. N Engl J Med 2007;356:895-903.

[83] Xing L, Kato K, Li T, Takeda N, Miyamura T, Hammar L, et al. Recombinant hepatitis E capsid protein self-assembles into a dual-domain T = 1 particle presenting native virus epitopes. Virology 1999;265:35-45.

[84] Dong C, Dai X, Meng JH. The first experimental study on a candidate combined vaccine against hepatitis A and hepatitis E. Vaccine 2007;25:1662-8.

[85] Perry RD, Fetherston JD. Yersinia pestis--etiologic agent of plague. Clin Microbiol Rev 1997;10:35-66.

[86] Williamson ED, Simpson AJ, Titball RW. Plague Vaccines. In: Plotkin SA, Orenstein WA, Offit PA, editors. Vaccines 5th ed. Philadelphia: Saunders,Elsevier, 2008: 519-29.

[87] Mudur G. India's pneumonic plague outbreak continues to baffle. BMJ 1995;311:706.

[88] Bertherat E, Lamine KM, Formenty P, Thuier P, Mondonge V, Mitifu A, et al. [Major pulmonary plague outbreak in a mining camp in the Democratic Republic of Congo: brutal awakening of an old scourge]. Med Trop (Mars) 2005;65:511-4.

[89] Prentice MB, Rahalison L. Plague. Lancet 2007;369:1196-207.

[90] Galimand M, Guiyoule A, Gerbaud G, Rasoamanana B, Chanteau S, Carniel E, et al. Multidrug resistance in Yersinia pestis mediated by a transferable plasmid. N Engl J Med 1997;337:677-80.

[91] Guiyoule A, Gerbaud G, Buchrieser C, Galimand M, Rahalison L, Chanteau S, et al. Transferable plasmid-mediated resistance to streptomycin in a clinical isolate of Yersinia pestis. Emerg Infect Dis 2001;7:43-8.

[92] Hinnebusch BJ, Rosso ML, Schwan TG, Carniel E. High-frequency conjugative transfer of antibiotic resistance genes to Yersinia pestis in the flea midgut. Mol Microbiol 2002;46:349-54.

[93] Inglesby TV, Dennis DT, Henderson DA, Bartlett JG, Ascher MS, Eitzen E, et al. Plague as a biological weapon: medical and public health management. Working Group on Civilian Biodefense. JAMA 2000;283:2281-90.

[94] Sebbane F, Jarrett CO, Gardner D, Long D, Hinnebusch BJ. Role of the Yersinia pestis plasminogen activator in the incidence of distinct septicemic and bubonic forms of flea-borne plague. Proc Natl Acad Sci U S A 2006;103:5526-30.

[95] Kool JL. Risk of person-to-person transmission of pneumonic plague. Clin Infect Dis 2005;40:1166-72.

[96] Koirala J. Plague: disease, management, and recognition of act of terrorism. Infect Dis Clin North Am 2006;20:273-87.

[97] Thomas RJ, Webber D, Collinge A, Stagg AJ, Bailey SC, Nunez A, et al. Different pathologies but equal levels of responsiveness to the recombinant F1 and V antigen vaccine and ciprofloxacin in a murine model of plague caused by small- and large-particle aerosols. Infect Immun 2009;77:1315-23.

[98] Sebbane F, Gardner D, Long D, Gowen BB, Hinnebusch BJ. Kinetics of disease progression and host response in a rat model of bubonic plague. Am J Pathol 2005;166:1427-39.

[99] Lathem WW, Crosby SD, Miller VL, Goldman WE. Progression of primary pneumonic plague: a mouse model of infection, pathology, and bacterial transcriptional activity. Proc Natl Acad Sci U S A 2005;102:17786-91.

[100] Bubeck SS, Cantwell AM, Dube PH. Delayed inflammatory response to primary pneumonic plague occurs in both outbred and inbred mice. Infect Immun 2007;75:697-705.

[101] Smiley ST. Current challenges in the development of vaccines for pneumonic plague. Expert Rev Vaccines 2008;7:209-21.

[102] Cornelis GR. Yersinia type III secretion: send in the effectors. J Cell Biol 2002;158:401-8.

[103] Brubaker RR. Interleukin-10 and inhibition of innate immunity to Yersiniae: roles of Yops and LcrV (V antigen). Infect Immun 2003;71:3673-81.

[104] Viboud GI, Bliska JB. Yersinia outer proteins: role in modulation of host cell signaling responses and pathogenesis. Annu Rev Microbiol 2005;59:69-89.

[105] Heesemann J, Sing A, Trulzsch K. Yersinia's stratagem: targeting innate and adaptive immune defense. Curr Opin Microbiol 2006;9:55-61.

[106] Marketon MM, DePaolo RW, DeBord KL, Jabri B, Schneewind O. Plague bacteria target immune cells during infection. Science 2005;309:1739-41.

[107] Price SB, Cowan C, Perry RD, Straley SC. The Yersinia pestis V antigen is a regulatory protein necessary for Ca2(+)-dependent growth and maximal expression of low-Ca2+ response virulence genes. J Bacteriol 1991;173:2649-57.

[108] Nakajima R, Motin VL, Brubaker RR. Suppression of cytokines in mice by protein A-V antigen fusion peptide and restoration of synthesis by active immunization. Infect Immun 1995;63:3021-9.

[109] Sing A, Rost D, Tvardovskaia N, Roggenkamp A, Wiedemann A, Kirschning CJ, et al. Yersinia V-antigen exploits toll-like receptor 2 and CD14 for interleukin 10-mediated immunosuppression. J Exp Med 2002;196:1017-24.

[110] Redpath S, Ghazal P, Gascoigne NR. Hijacking and exploitation of IL-10 by intracellular pathogens. Trends Microbiol 2001;9:86-92.

[111] Nakajima R, Brubaker RR. Association between virulence of Yersinia pestis and suppression of gamma interferon and tumor necrosis factor alpha. Infect Immun 1993;61:23-31.

[112] Sebbane F, Jarrett C, Gardner D, Long D, Hinnebusch BJ. The Yersinia pestis caf1M1A1 fimbrial capsule operon promotes transmission by flea bite in a mouse model of bubonic plague. Infect Immun 2009;77:1222-9.

[113] Bubeck SS, Dube PH. Yersinia pestis CO92 delta yopH is a potent live, attenuated plague vaccine. Clin Vaccine Immunol 2007;14:1235-8.

[114] Sha J, Agar SL, Baze WB, Olano JP, Fadl AA, Erova TE, et al. Braun lipoprotein (Lpp) contributes to virulence of yersiniae: potential role of Lpp in inducing bubonic and pneumonic plague. Infect Immun 2008;76:1390-409.

[115] Meyer KF. Effectiveness of live or killed plague vaccines in man. Bull World Health Organ 1970;42:653-66.

[116] Cavanaugh DC, Elisberg BL, Llewellyn CH, Marshall JD, Jr., Rust JH, Jr., Williams JE, et al. Plague immunization. V. Indirect evidence for the efficacy of plague vaccine. J Infect Dis 1974;129:Suppl:S37-40.

[117] Williamson ED. Plague vaccine research and development. J Appl Microbiol 2001;91:606-8.

[118] Girard G. Plague. Annu Rev Microbiol 1955;9:253-76.

[119] Girard G. [Immunity in Plague. Acquisitions Supplied by 30 Years of Work on the "Pasteurella Pestis Ev" (Girard and Robic) Strain.]. Biol Med (Paris) 1963;52:631-731.

[120] Russell P, Eley SM, Hibbs SE, Manchee RJ, Stagg AJ, Titball RW. A comparison of Plague vaccine, USP and EV76 vaccine induced protection against Yersinia pestis in a murine model. Vaccine 1995;13:1551-6.

[121] Meyer KF, Smith G, Foster L, Brookman M, Sung M. Live, attenuated Yersinia pestis vaccine: virulent in nonhuman primates, harmless to guinea pigs. J Infect Dis 1974;129:Suppl:S85-12.

[122] Zilinskas RA. The anti-plague system and the Soviet biological warfare program. Crit Rev Microbiol 2006;32:47-64.

[123] Cornelius C, Quenee L, Anderson D, Schneewind O. Protective immunity against plague. Adv Exp Med Biol 2007;603:415-24.

[124] Feodorova VA, Pan'kina LN, Savostina EP, Sayapina LV, Motin VL, Dentovskaya SV, et al. A Yersinia pestis lpxM-mutant live vaccine induces enhanced immunity against bubonic plague in mice and guinea pigs. Vaccine 2007;25:7620-8.

[125] Blisnick T, Ave P, Huerre M, Carniel E, Demeure CE. Oral vaccination against bubonic plague using a live avirulent Yersinia pseudotuberculosis strain. Infect Immun 2008;76:3808-16.

[126] Ehrenkranz NJ, Meyer KF. Studies on immunization against plague. VIII. Study of three immunizing preparations in protecting primates against pneumonic plague. J Infect Dis 1955;96:138-44.

[127] Andrews GP, Heath DG, Anderson GW, Jr., Welkos SL, Friedlander AM. Fraction 1 capsular antigen (F1) purification from Yersinia pestis CO92 and from an Escherichia coli recombinant strain and efficacy against lethal plague challenge. Infect Immun 1996;64:2180-7.

[128] Anderson GW, Jr., Worsham PL, Bolt CR, Andrews GP, Welkos SL, Friedlander AM, et al. Protection of mice from fatal bubonic and pneumonic plague by passive immunization with monoclonal antibodies against the F1 protein of Yersinia pestis. Am J Trop Med Hyg 1997;56:471-3.

[129] Friedlander AM, Welkos SL, Worsham PL, Andrews GP, Heath DG, Anderson GW, Jr., et al. Relationship between virulence and immunity as revealed in recent studies of the F1 capsule of Yersinia pestis. Clin Infect Dis 1995;21 Suppl 2:S178-81.

[130] Davis KJ, Fritz DL, Pitt ML, Welkos SL, Worsham PL, Friedlander AM. Pathology of experimental pneumonic plague produced by fraction 1-positive and fraction 1-negative Yersinia pestis in African green monkeys (Cercopithecus aethiops). Arch Pathol Lab Med 1996;120:156-63.

[131] Quenee LE, Cornelius CA, Ciletti NA, Elli D, Schneewind O. Yersinia pestis caf1 variants and the limits of plague vaccine protection. Infect Immun 2008;76:2025-36.

[132] Une T, Brubaker RR. Roles of V antigen in promoting virulence and immunity in yersiniae. J Immunol 1984;133:2226-30.

[133] Lee VT, Tam C, Schneewind O. LcrV, a substrate for Yersinia enterocolitica type III secretion, is required for toxin targeting into the cytosol of HeLa cells. J Biol Chem 2000;275:36869-75.

[134] Motin VL, Nakajima R, Smirnov GB, Brubaker RR. Passive immunity to yersiniae mediated by anti-recombinant V antigen and protein A-V antigen fusion peptide. Infect Immun 1994;62:4192-201.

[135] Leary SE, Williamson ED, Griffin KF, Russell P, Eley SM, Titball RW. Active immunization with recombinant V antigen from Yersinia pestis protects mice against plague. Infect Immun 1995;63:2854-8.

[136] Anderson GW, Jr., Leary SE, Williamson ED, Titball RW, Welkos SL, Worsham PL, et al. Recombinant V antigen protects mice against pneumonic and bubonic plague caused by F1-capsule-positive and -negative strains of Yersinia pestis. Infect Immun 1996;64:4580-5.

[137] Jones SM, Griffin KF, Hodgson I, Williamson ED. Protective efficacy of a fully recombinant plague vaccine in the guinea pig. Vaccine 2003;21:3912-8.

[138] Hill J, Copse C, Leary S, Stagg AJ, Williamson ED, Titball RW. Synergistic protection of mice against plague with monoclonal antibodies specific for the F1 and V antigens of Yersinia pestis. Infect Immun 2003;71:2234-8.

[139] Zauberman A, Cohen S, Levy Y, Halperin G, Lazar S, Velan B, et al. Neutralization of Yersinia pestis-mediated macrophage cytotoxicity by anti-LcrV antibodies and its correlation with protective immunity in a mouse model of bubonic plague. Vaccine 2008;26:1616-25.

[140] Overheim KA, Depaolo RW, Debord KL, Morrin EM, Anderson DM, Green NM, et al. LcrV plague vaccine with altered immunomodulatory properties. Infect Immun 2005;73:5152-9.

[141] DeBord KL, Anderson DM, Marketon MM, Overheim KA, DePaolo RW, Ciletti NA, et al. Immunogenicity and protective immunity against bubonic plague and pneumonic plague by immunization of mice with the recombinant V10 antigen, a variant of LcrV. Infect Immun 2006;74:4910-4.

[142] Williamson ED, Sharp GJ, Eley SM, Vesey PM, Pepper TC, Titball RW, et al. Local and systemic immune response to a microencapsulated sub-unit vaccine for plague. Vaccine 1996;14:1613-9.

[143] Williamson ED, Eley SM, Stagg AJ, Green M, Russell P, Titball RW. A sub-unit vaccine elicits IgG in serum, spleen cell cultures and bronchial washings and protects immunized animals against pneumonic plague. Vaccine 1997;15:1079-84.

[144] Heath DG, Anderson GW, Jr., Mauro JM, Welkos SL, Andrews GP, Adamovicz J, et al. Protection against experimental bubonic and pneumonic plague by a recombinant capsular F1-V antigen fusion protein vaccine. Vaccine 1998;16:1131-7.

[145] Jones SM, Day F, Stagg AJ, Williamson ED. Protection conferred by a fully recombinant sub-unit vaccine against Yersinia pestis in male and female mice of four inbred strains. Vaccine 2000;19:358-66.

[146] Jones T, Adamovicz JJ, Cyr SL, Bolt CR, Bellerose N, Pitt LM, et al. Intranasal Protollin/F1-V vaccine elicits respiratory and serum antibody responses and protects mice against lethal aerosolized plague infection. Vaccine 2006;24:1625-32.

[147] Cornelius CA, Quenee LE, Overheim KA, Koster F, Brasel TL, Elli D, et al. Immunization with recombinant V10 protects cynomolgus macaques from lethal pneumonic plague. Infect Immun 2008;76:5588-97.

[148] Williamson ED, Flick-Smith HC, Waters E, Miller J, Hodgson I, Le Butt CS, et al. Immunogenicity of the rF1+rV vaccine for plague with identification of potential immune correlates. Microb Pathog 2007;42:11-21.

[149] Rocke TE, Smith S, Marinari P, Kreeger J, Enama JT, Powell BS. Vaccination with F1-V fusion protein protects black-footed ferrets (Mustela nigripes) against plague upon oral challenge with Yersinia pestis. J Wildl Dis 2008;44:1-7.

[150] Williamson ED, Flick-Smith HC, Lebutt C, Rowland CA, Jones SM, Waters EL, et al. Human immune response to a plague vaccine comprising recombinant F1 and V antigens. Infect Immun 2005;73:3598-608.

[151] Morris SR. Development of a recombinant vaccine against aerosolized plague. Vaccine 2007;25:3115-7.

[152] Huang J, D'Souza AJ, Alarcon JB, Mikszta JA, Ford BM, Ferriter MS, et al. Protective immunity in mice achieved with dry powder formulation and alternative delivery of plague F1-V vaccine. Clin Vaccine Immunol 2009;16:719-25.

[153] DuBois AB, Freytag LC, Clements JD. Evaluation of combinatorial vaccines against anthrax and plague in a murine model. Vaccine 2007;25:4747-54.

[154] Smiley ST. Immune defense against pneumonic plague. Immunol Rev 2008;225:256-71.

[155] Titball RW, Williamson ED. Yersinia pestis (plague) vaccines. Expert Opin Biol Ther 2004;4:965-73.

[156] Goodin JL, Nellis DF, Powell BS, Vyas VV, Enama JT, Wang LC, et al. Purification and protective efficacy of monomeric and modified Yersinia pestis capsular F1-V antigen fusion proteins for vaccination against plague. Protein Expr Purif 2007;53:63-79.

[157] Mizel SB, Graff AH, Sriranganathan N, Ervin S, Lees CJ, Lively MO, et al. Flagellin-F1-V fusion protein is an effective plague vaccine in mice and two species of nonhuman primates. Clin Vaccine Immunol 2009;16:21-8.

[158] Airhart CL, Rohde HN, Hovde CJ, Bohach GA, Deobald CF, Lee SS, et al. Lipid A mimetics are potent adjuvants for an intranasal pneumonic plague vaccine. Vaccine 2008;26:5554-61.

[159] Elvin SJ, Eyles JE, Howard KA, Ravichandran E, Somavarappu S, Alpar HO, et al. Protection against bubonic and pneumonic plague with a single dose microencapsulated sub-unit vaccine. Vaccine 2006;24:4433-9.

[160] Yamanaka H, Hoyt T, Yang X, Golden S, Bosio CM, Crist K, et al. A nasal interleukin-12 DNA vaccine coexpressing Yersinia pestis F1-V fusion protein confers protection against pneumonic plague. Infect Immun 2008;76:4564-73.

[161] Yamanaka H, Hoyt T, Bowen R, Yang X, Crist K, Golden S, et al. An IL-12 DNA vaccine co-expressing Yersinia pestis antigens protects against pneumonic plague. Vaccine 2009;27:80-7.

[162] Oyston PC, Williamson ED, Leary SE, Eley SM, Griffin KF, Titball RW. Immunization with live recombinant Salmonella typhimurium aroA producing F1 antigen protects against plague. Infect Immun 1995;63:563-8.

[163] Titball RW, Howells AM, Oyston PC, Williamson ED. Expression of the Yersinia pestis capsular antigen (F1 antigen) on the surface of an aroA mutant of Salmonella typhimurium induces high levels of protection against plague. Infect Immun 1997;65:1926-30.

[164] Leary SE, Griffin KF, Garmory HS, Williamson ED, Titball RW. Expression of an F1/V fusion protein in attenuated Salmonella typhimurium and protection of mice against plague. Microb Pathog 1997;23:167-79.

[165] Garmory HS, Griffin KF, Brown KA, Titball RW. Oral immunisation with live aroA attenuated Salmonella enterica serovar Typhimurium expressing the Yersinia pestis V antigen protects mice against plague. Vaccine 2003;21:3051-7.

[166] Yang X, Hinnebusch BJ, Trunkle T, Bosio CM, Suo Z, Tighe M, et al. Oral vaccination with salmonella simultaneously expressing Yersinia pestis F1 and V antigens protects against bubonic and pneumonic plague. J Immunol 2007;178:1059-67.

[167] Palin A, Chattopadhyay A, Park S, Delmas G, Suresh R, Senina S, et al. An optimized vaccine vector based on recombinant vesicular stomatitis virus gives high-level, long-term protection against Yersinia pestis challenge. Vaccine 2007;25:741-50.

[168] Chiuchiolo MJ, Boyer JL, Krause A, Senina S, Hackett NR, Crystal RG. Protective immunity against respiratory tract challenge with Yersinia pestis in mice immunized with an adenovirus-based vaccine vector expressing V antigen. J Infect Dis 2006;194:1249-57.

[169] Arlen PA, Singleton M, Adamovicz JJ, Ding Y, Davoodi-Semiromi A, Daniell H. Effective plague vaccination via oral delivery of plant cells expressing F1-V antigens in chloroplasts. Infect Immun 2008;76:3640-50.

[170] Plotkin SA, Koprowski H, Rupprecht CE. Rabies vaccine. In: Plotkin SA, Orenstein WA, Offit PA, editors. Vaccines 5th ed. Philadelphia Saunders,Elsevier, 2008: 687-714.

[171] World Health Organ (WHO). Expert Consultation on Rabies. Geneva; 2005 5-8 October 2004.

[172] World Health Organ (WHO). Rabies Facts in short. Geneva; 2006.

[173] Meslin FX, Fishbein DB, Matter HC. Rationale and prospects for rabies elimination in developing countries. Curr Top Microbiol Immunol 1994;187:1-26.

[174] Knobel DL, Cleaveland S, Coleman PG, Fevre EM, Meltzer MI, Miranda ME, et al. Re-evaluating the burden of rabies in Africa and Asia. Bull World Health Organ 2005;83:360-8.

[175] WHO. Initiative for Virus Research (WHO). Proceedings of the 7th Global Vaccine Research Forum. Bangkok; 2006

[176] Sudarshan MK, Madhusudana SN, Mahendra BJ, Rao NS, Ashwath Narayana DH, Abdul Rahman S, et al. Assessing the burden of human rabies in India: results of a national multi-center epidemiological survey. Int J Infect Dis 2007;11:29-35.

[177] Anderson LJ, Nicholson KG, Tauxe RV, Winkler WG. Human rabies in the United States, 1960 to 1979: epidemiology, diagnosis, and prevention. Ann Intern Med 1984;100:728-35.

[178] Messenger SL, Smith JS, Rupprecht CE. Emerging epidemiology of bat-associated cryptic cases of rabies in humans in the United States. Clin Infect Dis 2002;35:738-47.

[179] Fuenzalida E, Palacios R, Borgono JM. Antirabies Antibody Response in Man to Vaccine Made from Infected Suckling-Mouse Brains. Bull World Health Organ 1964;30:431-6.

[180] Plotkin SA, Wiktor T. Rabies vaccination. Annu Rev Med 1978;29:583-91.

[181] Montagnon BJ. Polio and rabies vaccines produced in continuous cell lines: a reality for Vero cell line. Dev Biol Stand 1989;70:27-47.

[182] Ajjan N, Pilet C. Comparative study of the safety and protective value, in pre-exposure use, of rabies vaccine cultivated on human diploid cells (HDCV) and of the new vaccine grown on Vero cells. Vaccine 1989;7:125-8.

[183] Suwansrinon K, Wilde H, Benjavongkulchai M, Banjongkasaena U, Lertjarutorn S, Boonchang S, et al. Survival of neutralizing antibody in previously rabies vaccinated subjects: a prospective study showing long lasting immunity. Vaccine 2006;24:3878-80.

[184] Nagarajan T, Rupprecht CE, Dessain SK, Rangarajan PN, Thiagarajan D, Srinivasan VA. Human monoclonal antibody and vaccine approaches to prevent human rabies. Curr Top Microbiol Immunol 2008;317:67-101.

[185] Bakker AB, Python C, Kissling CJ, Pandya P, Marissen WE, Brink MF, et al. First administration to humans of a monoclonal antibody cocktail against rabies virus: safety, tolerability, and neutralizing activity. Vaccine 2008;26:5922-7.

[186] Turner GS, Aoki FY, Nicholson KG, Tyrrell DA, Hill LE. Human diploid cell strain rabies vaccine. Rapid prophylactic immunisation of volunteers with small doses. Lancet 1976;1:1379-81.

[187] Kamoltham T, Khawplod P, Wilde H. Rabies intradermal post-exposure vaccination of humans using reconstituted and stored vaccine. Vaccine 2002;20:3272-6.

[188] Warrell MJ, Nicholson KG, Warrell DA, Suntharasamai P, Chanthavanich P, Viravan C, et al. Economical multiple-site intradermal immunisation with human diploid-cell-strain vaccine is effective for post-exposure rabies prophylaxis. Lancet 1985;1:1059-62.

[189] Briggs DJ, Banzhoff A, Nicolay U, Sirikwin S, Dumavibhat B, Tongswas S, et al. Antibody response of patients after postexposure rabies vaccination with small intradermal doses of purified chick embryo cell vaccine or purified Vero cell rabies vaccine. Bull World Health Organ 2000;78:693-8.

[190] Madhusudana SN, Anand NP, Shamsundar R. Economical multi-site intradermal regimen with purified chick embryo cell vaccine (Rabipur) prevents rabies in people bitten by confirmed rabid animals. Int J Infect Dis 2002;6:210-4.

[191] World Health Organ (WHO). Detailed Guidelines to pre- and post-exposure prophylaxis. Geneva 2007

[192] Madhusudana SN, Sanjay TV, Mahendra BJ, Sudarshan MK, Narayana DH, Giri A, et al. Comparison of safety and immunogenicity of purified chick embryo cell rabies vaccine (PCECV) and purified vero cell rabies vaccine (PVRV) using the Thai Red Cross intradermal regimen at a dose of 0.1 ML. Hum Vaccin 2006;2:200-4.

[193] Ambrozaitis A, Laiskonis A, Balciuniene L, Banzhoff A, Malerczyk C. Rabies post-exposure prophylaxis vaccination with purified chick embryo cell vaccine (PCECV) and purified Vero cell rabies vaccine (PVRV) in a four-site intradermal schedule (4-0-2-0-1-1): an immunogenic, cost-effective and practical regimen. Vaccine 2006;24:4116-21.

[194] World Health Organ (WHO) Rabies vaccines. Weekly Epidemiol Rec 2007;82:425-36.

[195] Dutta JK, Warrell MJ, Dutta TK. Intradermal rabies immunization for pre- and post-exposure prophylaxis. Natl Med J India 1994;7:119-22.

[196] Kamoltham T, Thinyounyong W, Phongchamnaphai P, Phraisuwan P, Khawplod P, Banzhoff A, et al. Pre-exposure rabies vaccination using purified chick embryo cell rabies vaccine intradermally is immunogenic and safe. J Pediatr 2007;151:173-7.

[197] Roukens AH, Vossen AC, van Dissel JT, Visser LG. Reduced dose pre-exposure primary and booster intradermal rabies vaccination with a purified chick embryo cell vaccine (PCECV) is immunogenic and safe in adults. Vaccine 2008;26:3438-42.

[198] Khawplod P, Wilde H, Benjavongkulchai M, Sriaroon C, Chomchey P. Immunogenicity study of abbreviated rabies preexposure vaccination schedules. J Travel Med 2007;14:173-6.

[199] Khawplod P, Wilde H, Sirikwin S, Benjawongkulchai M, Limusanno S, Jaijaroensab W, et al. Revision of the Thai Red Cross intradermal rabies post-exposure regimen by eliminating the 90-day booster injection. Vaccine 2006;24:3084-6.

[200] Khawplod P, Wilde H, Sriaroon C, Chomchey P, Kamolthum T, Sitprija V. One or three intradermal injections within one week for rabies pre-exposure immunization. Dev Biol (Basel) 2008;131:393-401.

[201] Cleaveland S, Kaare M, Tiringa P, Mlengeya T, Barrat J. A dog rabies vaccination campaign in rural Africa: impact on the incidence of dog rabies and human dog-bite injuries. Vaccine 2003;21:1965-73.

[202] Cliquet F, Barrat J, Guiot AL, Cael N, Boutrand S, Maki J, et al. Efficacy and bait acceptance of vaccinia vectored rabies glycoprotein vaccine in captive foxes (Vulpes vulpes), raccoon dogs (Nyctereutes procyonoides) and dogs (Canis familiaris). Vaccine 2008;26:4627-38.

[203] Boulanger JR, Bigler LL, Curtis PD, Lein DH, Lembo AJ, Jr. Comparison of suburban vaccine distribution strategies to control raccoon rabies. J Wildl Dis 2008;44:1014-23.

[204] Shwiff SA, Kirkpatrick KN, Sterner RT. Economic evaluation of an oral rabies vaccination program for control of a domestic dog-coyote rabies epizootic: 1995-2006. J Am Vet Med Assoc 2008;233:1736-41.

[205] Ramey PC, Blackwell BF, Gates RJ, Slemons RD. Oral rabies vaccination of a northern Ohio raccoon population: relevance of population density and prebait serology. J Wildl Dis 2008;44:553-68.

[206] World Health Organ (WHO). Guidelines for oral vaccination of dogs against rabies without cover. Geneva; 2007.

[207] Rupprecht CE, Barrett J, Briggs D, Cliquet F, Fooks AR, Lumlertdacha B, et al. Can rabies be eradicated? Dev Biol (Basel) 2008;131:95-121.

Zoonotic Infections: 1,2,3,4,5,6